Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 225 Dyer St, Providence,rhode Island 02903,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Providence, Rhode Island
Bolden Therapeutics Questions
Bolden Therapeutics's website is http://www.boldentherapeutics.com
Bolden Therapeutics's LinkedIn profile is https://www.linkedin.com/company/bolden-therapeutics
Bolden Therapeutics has
3 employees.
View email and phone details for 3
employees at Bolden Therapeutics.
Bolden Therapeutics's industry is
Biotechnology Research
Bolden Therapeutics's top competitors are
Prisere,
Thrive Bioscience, Inc.,
Seranova Bio,
Mighty Well,
Gate Bioscience,
Mindimmune Therapeutics, Inc.,
Lift Biosciences,
Matter Bio,
Octagon Therapeutics,
Simcha Therapeutics.
Bolden Therapeutics's categories are Biotechnology Research
Bolden Therapeutics's founding year is 2019
